 |
My Story |
 |
| |
|
|
 |
|
 |
|
|
Glutathione and Parkinson's Disease:
Glutathione augmentation appears to be beneficial in Parkinson's disease. Although data suggests that milk (primarily pasteurized milk) appears to be associated with an increased incidence of PD, glutathione augmentation in Parkinson's Disease (which can be accomplished with bioactive whey protein, a fraction or isolate of unpasteurized milk) appears to offer some benefit.
- Sechi G. Deledda MG; Bua G; Satta WM; Deiana GA; Pes GM; Rosati G, Reduced intravenous glutathione in the treatment of early Parkinson’s disease. Prog Neurophyschopharmacol Biol Psychiatry, 20(7); 1159-70 1996 Oct.
- SpinaMB; Cohen G, Dopamine turnover and glutathione oxidation: implications for Parkinson’s disease, Proc Natl Acad Sci U S A, 86(4):1398-400 1989 Feb.
- Johannsen P; Velander G; Mai J; Thorling EB; Dupont E, Glutathione peroxidase in early and advanced Parkinson’s disease. J Neurol Neurosurg Psychiatry, 54 (8); 679-82 1991 Aug.
- Sian J; Dexter DT; Lees AJ; Daniel S; Agid Y; Javoy-Agid F; Jenner P; Marsden CD, Alterations in glutathione levels in Parkinson’s disease and other neurodegenerative disorders affecting basal ganglia, Ann Neurol, 36(3):348-55 1994 Sep.
- Di Monte DA; Chan P; Sandy MS, Glutathione in Parkinson’s disease: a link between oxidative stress and mitochondrial damage? Ann Neurol, 32 Suppl: S111-5 1992.
More information on Glutathione and neurodegenerative diseases:
- Samiec P.S., Drews-Botsch C., Flagg E.W., Kutz J.C., Sternberg P. Jr., Reed R.L., and Jones D.P., Glutathione in human plasma: decline in association with aging, age-related macular degeneration, and diabetes, Free Radic Med (1998) 15;24(5):699-704.
- De Mattia G; Bravi M.C.; Laurenti O; Cassone-Faldetta M; Armiento A; Ferri C; Balsano F, Influence of reduced glutathione infusion on glucose metabolism in patients with non-insulin-dependent diabetes mellitus, Metabolism 1998; 7(8):993-7.
- Arosio, Enrico, MD; De marchi, Sergio, MD; Zannoni, Massimo, Prior, MD; and Lechi, Alessandro, MD, Effect of Glutathione Infusion on Leg Arterial Circulation, Cutaneous Mircocirculation, and Pain-Free Walking Distance in Patients With Peripheral Obstructive Arterial Disease: A Randomized, Double-Blind, Placebo-Controlled Trial, Mayo Clin Proc. 2002; 77:754-759.
- Morocutti A; Sethi M; Hayward A; Lee A; Vererti G; Glutathione reverses the growth abnormalities of skin fibroblasts from insulin-dependent diabetic patients with nephropathy, J Am Soc Nephrol 1998; 9(6): 1060-6.
- Pearce R; Owen S; Daniel S; Jenner P; Marsden C, Alterations in the distribution of glutathione in substantia nigra in Parkinson’s disease, J Neural Transm 1997; 104:661-77.
- Perry T L; Godin D V; Hansen S; Jones K, Parkinson’s Disease: a disorder due to nigral cell glutathione deficiency, Neurosci Lett 1982; 33:300-10.
- Perry T L; Yong V, Idiopathic Parkinson’s disease, progressive supranuclear palsy and glutathione metabolism in substania nigra of patients, Neurosci Lett 1986; 67:269-74.
- Perry T L; Hansen S; Jones K, Brain amino acids and glutathione in progressive supranuclear palsy, Neurology 1988; 38:943-6.
- Calabrese V; Ragusa N; Antico A; Mangiameli S; Antico A; Mangiameli S; Rizza V; Cysteine-induced enhancement of lipid peroxidation in substania nigra: comparative effect with exogenous administration of reduced glutathione, Drugs Exp Clin Res 1997; 23(1):25-31.
- Riederer P; Sofic E; Rausch W; Schmidt B; Reynolds G; Jellinger K; Youdim M, Transition metals, ferrentin, glutathione, and ascorbic acid in pakinsonian brains, J Neurochem 1989; 52:515-520.
- Jenner P; Dexter D; Sian J; Schapira A; Marsden C; Oxidative stress as a cause of nigral cell death in Parkinson’s disease and incidental lewy body disease, Ann Neurol 1992; 32:S82-S87.
- Coppola L; Grassia A; Giunta R, Glutathione (GSH) improves hemostatic and hemorrheological parameters in atherosclerotic subjects, Drugs Exp Clin Res 1992; 18:493-98.
more information on milk and Parkinson's Disease
|
|
